PreveCeutical Medical Inc. has completed the fourth tranche of its non-brokered private placement, issuing 8.6 million units at $0.025 each, raising $215,000. This brings total proceeds from all four tranches to $1 million. Each unit includes one common share and half a warrant, allowing purchase of additional shares at $0.05 within two years, with an acceleration clause if share prices exceed $0.08. Funds will be used for loan repayments, legal and audit fees, patents, research, and general working capital. Securities issued are subject to a hold period and are not registered for sale in the U.S.
CoreWeave is generating $40 million in annualized revenue per megawatt, indicating strong demand and scarcity pricing for its GPU rental services. The company is diversifying beyond GPUs, with non-GPU products reaching over $400 million in annual rec...
In Germany, investors can buy XRP through three main methods: using a MiCA-authorised crypto exchange, a broker or neobroker app, or an exchange-traded product (ETP) held in a securities account. Only crypto exchanges and brokers provide actual XRP t...
Meta Platforms is set for long-term growth driven by its AI tools, custom MTIA chips, and subscription services like Meta One. These innovations leverage its massive user base of over 3 billion to generate recurring revenue and improve cost efficienc...
The Pacer US Cash Cows 100 ETF (COWZ) received a 'hold' rating because its growth and quality metrics lag behind those of VFLO, even though both ETFs have similar free cash flow yields. COWZ's strategy focuses on historical cash flows without forward...
Wesdome Gold is rated 'Buy' due to its potential resource upgrades and operational efficiencies amid strong gold prices. The company expects robust production of 180,000 ounces in 2024 and plans a significant $55 million exploration program in 2026. ...
